Spacelabs Medical Data announced today that William Wheeler, M.D., F.A.C.C., has joined the company as Medical Director.
Issaquah, Washington, June 17, 2005 . . . Spacelabs Medical Data announced today that William Wheeler, M.D., F.A.C.C., has joined the company as Medical Director. In addition to providing overall medical and scientific direction for the company, his responsibilities will include consultative services for protocol design and involvement in expert analyses of data, particularly in the realm of Thorough QT trials.
"The addition of Dr. Wheeler in this key position is extremely beneficial for our clients and gives us an important competitive edge," said Spacelabs Medical Data's General Manager Marc Hagan. "His expertise in cardiology is especially pertinent in pharmaceutical research today, with vital emphasis on the cardiac safety of new drug candidates."
Dr. Wheeler comes to Spacelabs Medical Data from Aderis Pharmaceuticals in Massachusetts, where he has been Vice President and Chief Medical Officer since 2001. At Aderis (formerly Discovery Therapeutics, Inc.), he was head of research, responsible for the formulation and implementation of all pre-clinical and clinical development programs. Aderis was involved in programs for Parkinson's disease, restless legs syndrome, pharmacologic stress testing, wound healing and atrial fibrillation. He previously served as Vice President for Cardiovascular/Critical Care at Quintiles, Inc.
"The Spacelabs Medical Data team provides exceptional ECG core laboratory capabilities for clinical trials. We have leveraged those core competencies to the performance and analysis of Thorough QT Studies. I'm proud to be a member of this team," said Dr. Wheeler.
He received his M.D. from the University of California at Los Angeles and completed his internship and residency at Los Angeles County/University of Southern California. He did his cardiology fellowship at Cedars Sinai Hospital in Los Angeles, California. Dr. Wheeler is an interventional cardiologist and board-certified in cardiovascular diseases and internal medicine. He has held academic appointments at multiple medical schools.
About Spacelabs Medical Data
Since its establishment in 1985 as a division of Spacelabs Medical, Inc., Spacelabs Medical Data has performed extensive cardiovascular procedures for virtually all of the major pharmaceutical companies, as well as biotech firms, universities, contract research organizations and device manufacturers. The company provides centralized monitoring, collection and analysis of data from ECG, Holter (ambulatory ECG), ABP (ambulatory blood pressure) monitors. Its cardiovascular specialists analyze and interpret cardiac physiological measurements that substantiate findings in the assessment of safety and/or efficacy of drug therapies. Spacelabs Medical, Inc. is an OSI Systems Company; www.osi-systems.com.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.